Is it the Right Time to Retain DGX Stock in Your Portfolio?
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Yahoo14 days agoDGX
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Yahoo14 days agoDGX
Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal
Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...
Yahoo15 days agoDGX
Is Quest Diagnostics (DGX) Still Worth A Look After A 92% Run?
Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...
Yahoo15 days agoDGX
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo17 days agoDGX
WHOOP Makes Advanced Labs Available Without a Wearable Membership
BOSTON, August 18, 2026--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX).
Yahoo17 days agoDGX
Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield
Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.
ChartMill17 days agoDGX
National Vision Stock Down Despite Q2 Earnings & Revenue Beat
EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.
Yahoo22 days agoDGX
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
Yahoo22 days agoDGX
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.
Yahoo23 days agoDGX
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.
Yahoo24 days agoDGX
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.
Yahoo24 days agoDGX
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
Yahoo25 days agoDGX
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
Yahoo25 days agoDGX
PBH Stock Up on Q1 Earnings and Revenue Beat, Fiscal '27 View Raised
Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.
Yahoo28 days agoDGX